To find out whether initiating the drug immediately after symptom onset would improve outcomes, researchers analyzed medical data from more than 80,000 patients in Hong Kong who used Paxlovid between March 2022 and January 2023.
By using Paxlovid between zero to one days after COVID-19 symptom onset, the rate of all-cause deaths and hospitalizations were half the rate of those recorded among delayed users, or those who took Paxlovid after two days.
The risk grew as more days passed since symptoms appeared, the researchers found. The incidence of 28-day all-cause deaths and hospitalizations was 5.1% for early initiators and 6.6% for delayed users.
A caveat was a risk of COVID-19 rebound that was higher among early users of Paxlovid, but this was “based on limited sample sizes and thus subject to high uncertainty,” the authors wrote.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
